Shandong Lukang Pharmaceutical Co Ltd (600789) - Total Liabilities
Based on the latest financial reports, Shandong Lukang Pharmaceutical Co Ltd (600789) has total liabilities worth CN¥4.57 Billion CNY (≈ $668.77 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see balance sheet size of Shandong Lukang Pharmaceutical Co Ltd.
Shandong Lukang Pharmaceutical Co Ltd - Total Liabilities Trend (1993–2025)
This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 600789 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Shandong Lukang Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Lukang Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hagar hf
IC:HAGA
|
Iceland | Ikr77.41 Billion |
|
Carlsberg Brewery Malaysia Bhd
KLSE:2836
|
Malaysia | RM729.80 Million |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥2.84 Billion |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
USA | $411.43 Million |
|
VIEL & Cie société anonyme
PA:VIL
|
France | €2.74 Billion |
|
Shanghai Electric Group Company Limited
F:USR
|
Germany | €247.42 Billion |
|
Guangdong South New Media Co Ltd
SHE:300770
|
China | CN¥1.16 Billion |
|
Universal Corporation
NYSE:UVV
|
USA | $1.61 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Shandong Lukang Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check 600789 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Lukang Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Lukang Pharmaceutical Co Ltd (1993–2025)
The table below shows the annual total liabilities of Shandong Lukang Pharmaceutical Co Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.78 Billion ≈ $699.08 Million |
-5.14% |
| 2024-12-31 | CN¥5.04 Billion ≈ $736.99 Million |
-0.49% |
| 2023-12-31 | CN¥5.06 Billion ≈ $740.60 Million |
-3.05% |
| 2022-12-31 | CN¥5.22 Billion ≈ $763.92 Million |
+18.91% |
| 2021-12-31 | CN¥4.39 Billion ≈ $642.45 Million |
+12.18% |
| 2020-12-31 | CN¥3.91 Billion ≈ $572.68 Million |
-0.10% |
| 2019-12-31 | CN¥3.92 Billion ≈ $573.27 Million |
+12.07% |
| 2018-12-31 | CN¥3.50 Billion ≈ $511.55 Million |
+12.66% |
| 2017-12-31 | CN¥3.10 Billion ≈ $454.08 Million |
+41.30% |
| 2016-12-31 | CN¥2.20 Billion ≈ $321.35 Million |
+3.93% |
| 2015-12-31 | CN¥2.11 Billion ≈ $309.20 Million |
-18.12% |
| 2014-12-31 | CN¥2.58 Billion ≈ $377.64 Million |
+5.77% |
| 2013-12-31 | CN¥2.44 Billion ≈ $357.05 Million |
+2.60% |
| 2012-12-31 | CN¥2.38 Billion ≈ $348.01 Million |
+33.03% |
| 2011-12-31 | CN¥1.79 Billion ≈ $261.60 Million |
+32.57% |
| 2010-12-31 | CN¥1.35 Billion ≈ $197.32 Million |
+44.94% |
| 2009-12-31 | CN¥930.38 Million ≈ $136.14 Million |
-7.01% |
| 2008-12-31 | CN¥1.00 Billion ≈ $146.41 Million |
-4.59% |
| 2007-12-31 | CN¥1.05 Billion ≈ $153.46 Million |
+4.18% |
| 2006-12-31 | CN¥1.01 Billion ≈ $147.31 Million |
-7.38% |
| 2005-12-31 | CN¥1.09 Billion ≈ $159.05 Million |
-9.62% |
| 2004-12-31 | CN¥1.20 Billion ≈ $175.99 Million |
+11.19% |
| 2003-12-31 | CN¥1.08 Billion ≈ $158.28 Million |
-1.78% |
| 2002-12-31 | CN¥1.10 Billion ≈ $161.14 Million |
-9.60% |
| 2001-12-31 | CN¥1.22 Billion ≈ $178.25 Million |
+6.90% |
| 2000-12-31 | CN¥1.14 Billion ≈ $166.74 Million |
+64.68% |
| 1999-12-31 | CN¥691.92 Million ≈ $101.25 Million |
+58.73% |
| 1998-12-31 | CN¥435.91 Million ≈ $63.79 Million |
-1.55% |
| 1997-12-31 | CN¥442.76 Million ≈ $64.79 Million |
+14.65% |
| 1996-12-31 | CN¥386.20 Million ≈ $56.51 Million |
+21.72% |
| 1995-12-31 | CN¥317.27 Million ≈ $46.43 Million |
+20.14% |
| 1994-12-31 | CN¥264.09 Million ≈ $38.64 Million |
+5.53% |
| 1993-12-31 | CN¥250.26 Million ≈ $36.62 Million |
-- |
About Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more